<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688740</url>
  </required_header>
  <id_info>
    <org_study_id>EFC6041</org_study_id>
    <secondary_id>XRP6976D-316</secondary_id>
    <secondary_id>BCIRG001</secondary_id>
    <nct_id>NCT00688740</nct_id>
  </id_info>
  <brief_title>Docetaxel in Node Positive Adjuvant Breast Cancer</brief_title>
  <acronym>TAX316</acronym>
  <official_title>A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer International Research Group (CIRG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare disease-free survival after treatment with docetaxel
      in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with
      doxorubicin and cyclophosphamide in operable breast cancer patients with positive axillary
      lymph nodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to the 5-year analysis conducted in September 2003, two other analyses were
      planned when 590 and 700 Disease Free Survival events occurred. However, due to the lower
      than predicted DFS event rate, and in agreement with FDA and EMA, a time-based final analysis
      at 10 years was considered more appropriate than an event-based (700 Disease Free Survival
      events) analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1997</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Disease-Free Survival Events</measure>
    <time_frame>up to 10 year follow-up</time_frame>
    <description>Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival Events</measure>
    <time_frame>up to 10 year follow-up</time_frame>
    <description>Overall Survival - time from the date of randomization up to the date of death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Second Primary Malignancies (Toxicity)</measure>
    <time_frame>up to 10 year follow-up</time_frame>
    <description>Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1491</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TAC (Docetaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel (75 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FAC (5-fluorouracil)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-fluorouracil (500 mg/m^2) in combination with doxorubicin (50 mg/m^2) and cyclophosphamide (500 mg/m^2) on day 1 every 3 weeks for 6 cycles of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>intravenous</description>
    <arm_group_label>TAC (Docetaxel)</arm_group_label>
    <other_name>TaxotereÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>intravenous</description>
    <arm_group_label>FAC (5-fluorouracil)</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>TAC (Docetaxel)</arm_group_label>
    <arm_group_label>FAC (5-fluorouracil)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>intravenous</description>
    <arm_group_label>TAC (Docetaxel)</arm_group_label>
    <arm_group_label>FAC (5-fluorouracil)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven breast cancer (invasive adenocarcinoma with at least one
             axillary lymph node showing evidence of tumor among a minimum of six resected lymph
             nodes).

          -  Definitive surgical treatment must be either mastectomy, or breast conserving surgery
             with axillary lymph node dissection for operable breast cancer. Margins of resected
             specimen from definitive surgery must be histologically free of invasive
             adenocarcinoma and ductal carcinoma.

        Exclusion criteria:

          -  Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy,
             chemotherapy).

          -  Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sanofi-aventis Administrative office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Porto Salvo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Midrand</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bromma</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis adminsitrative office</name>
      <address>
        <city>Guildford Surrey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Montevideo</city>
        <country>Uruguay</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Egypt</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
    <country>Uruguay</country>
  </location_countries>
  <results_reference>
    <citation>Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13.</citation>
    <PMID>15930421</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <results_first_submitted>January 25, 2011</results_first_submitted>
  <results_first_submitted_qc>January 25, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 14, 2011</results_first_posted>
  <last_update_submitted>February 14, 2011</last_update_submitted>
  <last_update_submitted_qc>February 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>Sanofi-aventis</organization>
  </responsible_party>
  <keyword>adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between June 1997 and June 1999, 1491 women from 20 countries were enrolled in the study. The last patient last visit occurred in January 2010.</recruitment_details>
      <pre_assignment_details>Eleven women (1 who had been randomly assigned to receive TAC and 10 assigned to receive FAC) did not receive any treatment for the following reasons: 8 withdrew consent, 1 was lost to follow-up, and 2 did not receive treatment for other reasons. In total 1480 patients (744 in the TAC group and 736 in the FAC group) were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TAC (Docetaxel)</title>
          <description>docetaxel in combination with doxorubicin and cyclophosphamide</description>
        </group>
        <group group_id="P2">
          <title>FAC (5-fluorouracil)</title>
          <description>5-fluorouracil in combination with doxorubicin and cyclophosphamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="745"/>
                <participants group_id="P2" count="746"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="679"/>
                <participants group_id="P2" count="711"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Breast Cancer Relapse</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Inclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TAC (Docetaxel)</title>
          <description>docetaxel in combination with doxorubicin and cyclophosphamide</description>
        </group>
        <group group_id="B2">
          <title>FAC (5-fluorouracil)</title>
          <description>5-fluorouracil in combination with doxorubicin and cyclophosphamide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="745"/>
            <count group_id="B2" value="746"/>
            <count group_id="B3" value="1491"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="697"/>
                    <measurement group_id="B2" value="705"/>
                    <measurement group_id="B3" value="1402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="745"/>
                    <measurement group_id="B2" value="746"/>
                    <measurement group_id="B3" value="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Positive Nodes</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1-3 Positive Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="467"/>
                    <measurement group_id="B2" value="459"/>
                    <measurement group_id="B3" value="926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 or More Positive Nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Disease-Free Survival Events</title>
        <description>Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.</description>
        <time_frame>up to 10 year follow-up</time_frame>
        <population>The study was originally designed to have 90% power to detect a 26% risk reduction of relapsing for TAC compared to FAC (hazard ratio=0.74)</population>
        <group_list>
          <group group_id="O1">
            <title>TAC (Docetaxel)</title>
            <description>docetaxel in combination with doxorubicin and cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>FAC (5-fluorouracil)</title>
            <description>5-fluorouracil in combination with doxorubicin and cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease-Free Survival Events</title>
          <description>Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.</description>
          <population>The study was originally designed to have 90% power to detect a 26% risk reduction of relapsing for TAC compared to FAC (hazard ratio=0.74)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="745"/>
                <count group_id="O2" value="746"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287" lower_limit="0.579" upper_limit="0.650"/>
                    <measurement group_id="O2" value="333" lower_limit="0.513" upper_limit="0.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <p_value_desc>Pairwise stratified log-rank test on the number of positive axillary nodes as per randomization</p_value_desc>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.795</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.679</ci_lower_limit>
            <ci_upper_limit>0.932</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival Events</title>
        <description>Overall Survival - time from the date of randomization up to the date of death of any cause.</description>
        <time_frame>up to 10 year follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAC (Docetaxel)</title>
            <description>docetaxel in combination with doxorubicin and cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>FAC (5-fluorouracil)</title>
            <description>5-fluorouracil in combination with doxorubicin and cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival Events</title>
          <description>Overall Survival - time from the date of randomization up to the date of death of any cause.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="745"/>
                <count group_id="O2" value="746"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" lower_limit="0.724" upper_limit="0.786"/>
                    <measurement group_id="O2" value="241" lower_limit="0.651" upper_limit="0.719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Pairwise stratified log-rank test on the number of positive axillary nodes as per randomization</p_value_desc>
            <method>Log Rank</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.742</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.613</ci_lower_limit>
            <ci_upper_limit>0.898</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Second Primary Malignancies (Toxicity)</title>
        <description>Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.</description>
        <time_frame>up to 10 year follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TAC (Docetaxel)</title>
            <description>docetaxel in combination with doxorubicin and cyclophosphamide</description>
          </group>
          <group group_id="O2">
            <title>FAC (5-fluorouracil)</title>
            <description>5-fluorouracil in combination with doxorubicin and cyclophosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Second Primary Malignancies (Toxicity)</title>
          <description>Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="745"/>
                <count group_id="O2" value="746"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from date of randomization until the completion of the 10-year follow-up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>TAC (Docetaxel)</title>
          <description>docetaxel in combination with doxorubicin and cyclophosphamide</description>
        </group>
        <group group_id="E2">
          <title>FAC (5-fluorouracil)</title>
          <description>5-fluorouracil in combination with doxorubicin and cyclophosphamide</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="267" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever in absence of infection</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Catheter related complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Trichomoniasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Breast infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Essential tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="744" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="734" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Any cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Any eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="167" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="713" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="709" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="599" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="647" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="508" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="374" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="436" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="255" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="205" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="132" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any general disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="673" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="610" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="592" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="513" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="312" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="264" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="250" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="152" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Fever in absence of infection</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Any immune system disorders</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Any infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Any investigations</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Any metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="140" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Any nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="427" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="206" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Any psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="214" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="170" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Any reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="307" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="268" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="211" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Any respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="280" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="117" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Any skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="734" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="718" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="728" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="715" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Any vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="194" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="736"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="744"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="736"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No publication of the study will be made without approval of the advisory board of the Breast Cancer International Research Group and Rhone- Poulenc Rorer.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>International Clinical Development Study Director</name_or_title>
      <organization>sanofi-aventis</organization>
      <email>Contact-us@sanofi-aventis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

